About Envoplakin
Envoplakin (EVPL) is a protein
from Homo sapiens identified by UniProt accession
Q92817, 2033 residues long.
MolForge cross-references it against 0 known binders and
131 disease associations.
Target properties
| Protein name | Envoplakin |
|---|
| UniProt accession | Q92817 |
|---|
| Gene | EVPL |
|---|
| Organism | Homo sapiens |
|---|
| Length | 2033 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (131)
Diseases linked to this target (Open Targets).
- white matter hyperintensity measurement · score 0.25
- lymphocyte count · score 0.23
- glioblastoma multiforme · score 0.23
- breast adenocarcinoma · score 0.22
- thyroid gland adenocarcinoma · score 0.19
- clear cell renal carcinoma · score 0.18
- head and neck squamous cell carcinoma · score 0.18
- ovarian cancer · score 0.18
- esophageal cancer · score 0.17
- gastric adenocarcinoma · score 0.16
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q92817-F1 | alphafold | PREDICTED | 71.70 | — |
Amino-acid sequence (2033 residues)
MFKGLSKGSQ GKGSPKGSPA KGSPKGSPSR HSRAATQELA LLISRMQANA DQVERDILET QKRLQQDRLN SEQSQALQHQ QETGRSLKEA EVLLKDLFLD VDKARRLKHP QAEEIEKDIK QLHERVTQEC AEYRALYEKM VLPPDVGPRV DWARVLEQKQ KQVCAGQYGP GMAELEQQIA EHNILQKEID AYGQQLRSLV GPDAATIRSQ YRDLLKAASW RGQSLGSLYT HLQGCTRQLS ALAEQQRRIL QQDWSDLMAD PAGVRREYEH FKQHELLSQE QSVNQLEDDG ERMVELRHPA VGPIQAHQEA LKMEWQNFLN LCICQETQLQ HVEDYRRFQE EADSVSQTLA KLNSNLDAKY SPAPGGPPGA PTELLQQLEA EEKRLAVTER ATGDLQRRSR DVAPLPQRRN PPQQPLHVDS ICDWDSGEVQ LLQGERYKLV DNTDPHAWVV QGPGGETKRA PAACFCIPAP DPDAVARASR LASELQALKQ KLATVQSRLK ASAVESLRPS QQAPSGSDLA NPQAQKLLTQ MTRLDGDLGQ IERQVLAWAR APLSRPTPLE DLEGRIHSHE GTAQRLQSLG TEKETAQKEC EAFLSTRPVG PAALQLPVAL NSVKNKFSDV QVLCSLYGEK AKAALDLERQ IQDADRVIRG FEATLVQEAP IPAEPGALQE RVSELQRQRR ELLEQQTCVL RLHRALKASE HACAALQNNF QEFCQDLPRQ QRQVRALTDR YHAVGDQLDL REKVVQDAAL TYQQFKNCKD NLSSWLEHLP RSQVRPSDGP SQIAYKLQAQ KRLTQEIQSR ERDRATASHL SQALQAALQD YELQADTYRC SLEPTLAVSA PKRPRVAPLQ ESIQAQEKNL AKAYTEVAAA QQQLLQQLEF ARKMLEKKEL SEDIRRTHDA KQGSESPAQA GRESEALKAQ LEEERKRVAR VQHELEAQRS QLLQLRTQRP LERLEEKEVV EFYRDPQLEG SLSRVKAQVE EEGKRRAGLQ ADLEVAAQKV VQLESKRKTM QPHLLTKEVT QVERDPGLDS QAAQLRIQIQ QLRGEDAVIS ARLEGLKKEL LALEKREVDV KEKVVVKEVV KVEKNLEMVK AAQALRLQME EDAARRKQAE EAVAKLQARI EDLERAISSV EPKVIVKEVK KVEQDPGLLQ ESSRLRSLLE EERTKNATLA RELSDLHSKY SVVEKQRPKV QLQERVHEIF QVDPETEQEI TRLKAKLQEM AGKRSGVEKE VEKLLPDLEV LRAQKPTVEY KEVTQEVVRH ERSPEVLREI DRLKAQLNEL VNSHGRSQEQ LIRLQGERDE WRRERAKVET KTVSKEVVRH EKDPVLEKEA ERLRQEVREA AQKRRAAEDA VYELQSKRLL LERRKPEEKV VVQEVVVTQK DPKLREEHSR LSGSLDEEVG RRRQLELEVQ QLRAGVEEQE GLLSFQEDRS KKLAVERELR QLTLRIQELE KRPPTVQEKI IMEEVVKLEK DPDLEKSTEA LRWDLDQEKT QVTELNRECK NLQVQIDVLQ KAKSQEKTIY KEVIRVQKDR VLEDERARVW EMLNRERTAR QAREEEARRL RERIDRAETL GRTWSREESE LQRARDQADQ ECGRLQQELR ALERQKQQQT LQLQEESKLL SQKTESERQK AAQRGQELSR LEAAILREKD QIYEKERTLR DLHAKVSREE LSQETQTRET NLSTKISILE PETGKDMSPY EAYKRGIIDR GQYLQLQELE CDWEEVTTSG PCGEESVLLD RKSGKQYSIE AALRCRRISK EEYHLYKDGH LPISEFALLV AGETKPSSSL SIGSIISKSP LASPAPQSTS FFSPSFSLGL GDDSFPIAGI YDTTTDNKCS IKTAVAKNML DPITGQKLLE AQAATGGIVD LLSRERYSVH KAMERGLIEN TSTQRLLNAQ KAFTGIEDPV TKKRLSVGEA VQKGWMPRES VLPHLQVQHL TGGLIDPKRT GRIPIQQALL SGMISEELAQ LLQDESSYEK DLTDPISKER LSYKEAMGRC RKDPLSGLLL LPAALEGYRC YRSASPTVPR SLR
Explore Envoplakin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets